ResearcherUniversity Hospital HeidelbergNo recent work listed
Jacek Hajda
Matched on ORCID iD 0000-0003-3907-5918; OpenAlex author ID A5000827518. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 3
- Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
- Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
- A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dirk Jäger · 3 shared papers, 2017–2023 · strength 0.29
- Paper Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemc… DOI 10.1111/cts.13661↗
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Christoph Springfeld · 3 shared papers, 2017–2023 · strength 0.29
- Paper Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemc… DOI 10.1111/cts.13661↗
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Nicolas Hohmann · 2 shared papers, 2021–2023 · strength 0.23
- Paper Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemc… DOI 10.1111/cts.13661↗
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Albrecht Stenzinger · 2 shared papers, 2017–2023 · strength 0.19
- Paper Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemc… DOI 10.1111/cts.13661↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Christine E. Engeland · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Guy Ungerechts · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Niels Halama · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Assia L. Angelova · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Karen Steindorf · 1 shared paper, 2023 · strength 0.14
- Martin Ronald Sprick · 1 shared paper, 2023 · strength 0.14
- Andreas Trumpp · 1 shared paper, 2023 · strength 0.14
- Azaz Ahmed · 1 shared paper, 2023 · strength 0.14
- Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.14
- Jens Thomas Siveke · 1 shared paper, 2023 · strength 0.14
- Matthias M. Gaida · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.